KAEL–GemVax Reports Encouraging Interim Progress in Phase II Study of GV1001 Anti-telomerase Vaccine in NSCLC
Published: Nov 15, 2011
SEOUL, South Korea--(BUSINESS WIRE)--KAEL-GemVax, a leading oncology biopharmaceutical company, today announced that results from a Phase II trial (CTN-2006) in Stage III non-small cell lung cancer (NSCLC) patients vaccinated with the telomerase peptide GV1001 after chemoradiotherapy and an 8-year update from a phase I/II trial have been published in the November issue of Clinical Cancer, the journal of the American Association for Cancer Research1. The study reports that that vaccination with GV1001 is well tolerated, immunizing the majority of NSCLC patients and establishing durable T-cell memory. The authors conclude that the survival advantage observed for immune responders warrants a randomised trial.